Exhibit 5.1

Faegre Drinker Biddle & Reath

LLP

2200 Wells Fargo Center

90 South Seventh Street

Minneapolis, Minnesota 55402

+1 612 766 7000 main

+1 612 766 1600 fax

May 26, 2021

Board of Directors

Stericycle, Inc.

2355 Waukegan Road

Bannockburn, Illinois 60015

Ladies and Gentlemen:

We have acted as counsel to Stericycle, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of the Post-Effective Amendment No. 1 (the “Amendment”) to each of the Company’s: Registration Statement on Form S-8 filed with the Commission on August 9, 2005 (Registration No. 333-127353) (the “2005 Registration Statement”), Registration Statement on Form S-8 filed with the Commission on August 8, 2008 (Registration No. 333-152877) (the “2008 Registration Statement”), Registration Statement on Form S-8 filed with the Commission on August 9, 2011 (Registration No. 333-176165) (the “2011 Registration Statement”), Registration Statement on Form S-8 filed with the Commission on December 23, 2014 (Registration No. 333-201236) (the “2014 Registration Statement”) and Registration Statement on Form S-8 filed with the Commission on January 26, 2018 (Registration No. 333-222735) (the “2018 Registration Statement,” and together with the 2005 Registration Statement, the 2008 Registration Statement, the 2011 Registration Statement and the 2014 Registration Statement, the “Registration Statements”) under the Securities Act of 1933, as amended (the “Act”).

The 2005 Registration Statement registered 2,400,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), reserved for issuance pursuant to the Stericycle, Inc. 2005 Incentive Stock Plan (the “2005 Plan”). The 2008 Registration Statement registered 3,500,000 shares of the Company’s Common Stock reserved for issuance pursuant to the Stericycle, Inc. 2008 Incentive Stock Plan (the “2008 Plan”), the 2011 Registration Statement registered 3,000,000 shares of the Company’s Common Stock reserved for issuance pursuant to the Stericycle, Inc. 2011 Incentive Stock Plan (the “2011 Plan”), the 2014 Registration Statement registered 2,500,000 shares of the Company’s Common Stock reserved for issuance pursuant to the Stericycle, Inc. 2014 Incentive Stock Plan (the “2014 Plan”) and the 2018 Registration Statement registered 1,500,000 shares of the Company’s Common Stock reserved for issuance pursuant to the Stericycle, Inc. 2017 Long-Term Incentive Plan (the “2017 Plan”).

The Amendment reflects that, pursuant to the terms of the Stericycle, Inc. 2021 Long-Term Incentive Plan (the “2021 Plan”), which was approved by the Company’s stockholders on May 26, 2021 (the “Effective Date”), the number of shares of the Company’s Common Stock for which awards may be granted under the 2021 Plan includes up to 2,144,494 shares of the Company’s Common Stock remaining available for future grants under the 2011 Plan, the 2014 Plan and the 2017 Plan (collectively, the “Prior Plans”) on the Effective Date and up to 2,187,077 shares of the Company’s Common Stock subject to awards granted under the 2005 Plan, the 2008 Plan or the Prior Plans that are outstanding on the Effective Date that subsequently expire, are canceled or forfeited, or are settled for cash (together, such 4,331,571 shares of the Company’s Common Stock are referred to herein as the “Carryover Shares”).

For purposes of this opinion letter, we have examined the 2005 Plan, the 2008 Plan, the Prior Plans, the 2021 Plan, the Registration Statements, the Amendment, the amended and restated certificate of incorporation of the Company, as currently in effect, the amended and restated bylaws of the Company, as currently in effect, and the resolutions of the Company’s board of directors authorizing the issuance of the Carryover Shares. We have also examined a certificate of the Secretary of the Company dated the date hereof (the “Certificate”) and originals, or copies certified or otherwise authenticated to our satisfaction, of such corporate records and other records, agreements, instruments, certificates of public officials and documents as we have deemed necessary as a basis for the opinions hereinafter expressed and have reviewed such matters of law as we have deemed relevant hereto. As to facts material to this opinion letter, we have relied upon certificates, statements or representations of public officials, of officers and representatives of the Company (including the Certificate) and of others, without any independent verification thereof.

In our examination, we have assumed: (i) the legal capacity of all natural persons; (ii) the genuineness of all signatures; (iii) the authenticity of all documents submitted to us as originals; (iv) the conformity to original documents of all documents submitted to us as certified, conformed, photostatic or facsimile copies; (v) the authenticity of the originals of such latter documents; (vi) the truth, accuracy and completeness of the information, representations and warranties contained in the agreements, documents, instruments, certificates and records we have reviewed; and (vii) the absence of any undisclosed modifications to the agreements and instruments reviewed by us.

Based upon such examination and review, and subject to the foregoing and the other qualifications, assumptions and limitations set forth herein, it is our opinion that all necessary corporate action on the part of the Company has been taken to authorize the issuance and sale of the Carryover Shares to be issued in accordance with the 2021 Plan and that, when (a) the Amendment shall have become effective, (b) the Carryover Shares have been issued and sold as contemplated in the Amendment and related prospectus and in accordance with the 2021 Plan and any applicable award agreement, and (c) where applicable, the consideration for the Carryover Shares specified in the 2021 Plan and any applicable award agreement has been received by the Company, the Carryover Shares will be legally and validly issued, fully paid and nonassessable.

The foregoing opinions are limited to the Delaware General Corporation Law and speak only as of the date the Amendment becomes effective under the Act, and we assume no obligation to revise or supplement this opinion thereafter. This opinion is limited to the specific issues addressed herein, and no opinion may be inferred or implied beyond that expressly stated herein.

We hereby consent to the filing of this opinion as an exhibit to the Amendment. In giving such consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,
FAEGRE DRINKER BIDDLE & REATH LLP
By:	/s/ W. Morgan Burns
	W. Morgan Burns
	Partner